Progyny, Inc. (PGNY) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Progyny, Inc. (PGNY) stock forecast summary
On Oct. 14, 2026, PGNY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Progyny, Inc. is a mid-cap company with a market capitalization of $2.10B. It ranks number 4 by market capitalization among the 11 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for PGNY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PGNY included.
Follow PGNY freePGNY price chart and AI forecast
How PGNY ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Progyny, Inc. (PGNY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | PGNY | Rank |
|---|---|---|
| Market Cap | $2.10B | 4/11 |
| P/E Ratio | 26.73x | 2/5 |
| P/B Ratio | 4.64x | 3/7 |
| EPS | $0.80 | – |
| Book Value/Share | $5.91 | – |
| Revenue/Share | $17.08 | – |
| FCF/Share | $2.32 | – |
Profitability & Margins
| Metric | PGNY | Rank |
|---|---|---|
| ROE | 17.4% | 2/7 |
| ROA | 11.0% | 1/10 |
| ROIC | 23.6% | 2/8 |
| Gross Margin | 24.5% | 6/6 |
| Operating Margin | 8.6% | 3/9 |
| Net Margin | 6.0% | 4/10 |
| EBT Margin | 9.1% | 4/10 |
| Tax Rate | 34.4% | – |
Financial Health
| Metric | PGNY | Rank |
|---|---|---|
| Current Ratio | 2.14x | 4/11 |
| D/E Ratio | 0.58x | 4/9 |
| Financial Leverage | 1.58x | 4/9 |
| Interest Coverage | 29.3x | 2/12 |
| Working Capital | $273M | 3/11 |
Cash Flow
| Metric | PGNY | Rank |
|---|---|---|
| Operating Cash Flow | $201M | 4/11 |
| Free Cash Flow | $178M | 2/7 |
| Capital Spending | -$23M | 4/7 |
| OCF Growth YoY | -0.4% | 5/7 |
| FCF Growth YoY | -6.2% | 3/5 |
| FCF/Sales | 13.6% | 2/7 |
| CapEx/Sales | 1.7% | 4/7 |
Operational Efficiency
| Metric | PGNY | Rank |
|---|---|---|
| Asset Turnover | 1.83x | 2/9 |
| Receivables Turnover | 5.1x | 7/9 |
| Fixed Assets Turnover | 31.2x | 3/8 |
| Days Sales Outstanding | 72 days | 3/9 |
| Payables Period | 56 days | 5/5 |
Income Statement
| Metric | PGNY | Rank |
|---|---|---|
| Total Revenue | $1.31B | 3/9 |
| Operating Income | $112M | 3/10 |
| Net Income | $78M | 3/10 |
| R&D Expense | $16M | 2/6 |
| SG&A Expense | $412M | 2/6 |
| Cost of Goods Sold | $989M | 2/8 |
Dividend & Shareholder Information
| Metric | PGNY | Rank |
|---|---|---|
| Shares Outstanding | 77M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $513M | 71.7% of assets |
| Cash & Short-term Investments | $153M | 21.3% of assets |
| Accounts Receivable | $257M | 36.0% of assets |
| Total Liabilities | $263M | 36.7% of assets |
| Short-term Debt | $88M | 12.3% of assets |
PGNY quarterly financials and insider trading
Progyny, Inc. (PGNY) industry peers
Companies classified under the same SEC industry code as Progyny, Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PGNY Progyny, Inc. | ▶ | $2.10B |
| DVA Davita Inc. | ▶ | $11.62B |
| FMS Fresenius Medical Care Ag | ▼ | $5.89B |
| SHC Sotera Health Co | ▼ | $5.20B |
| AGL Agilon Health, Inc. | ▶ | $1.44B |
| VMD Viemed Healthcare, Inc. | ▲ | $366M |
| PARK Park Dental Partners, Inc. | ▶ | $93M |
| MRAI Marpai, Inc. | ▲ | $86M |
| CCEL Cryo Cell International Inc | ▲ | $35M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| MGRX Mangoceuticals, Inc. | ▶ | $8M |
| BRTX Biorestorative Therapies, Inc. | ▶ | N/A |
| NIVF Newgenivf Group Ltd | ▼ | N/A |
Where PGNY sits on the market map
Progyny, Inc. (PGNY) stock news
Loading...
Progyny, Inc. (PGNY) stock forecast FAQ
What is the Progyny, Inc. (PGNY) stock forecast?
On Oct. 14, 2026, PGNY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Progyny, Inc. stock predictions?
A per-ticker accuracy statistic for PGNY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Progyny, Inc. forecasts updated?
Progyny, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Progyny, Inc.'s industry peers?
13 issuers in our coverage, PGNY included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Davita Inc. (DVA), Fresenius Medical Care Ag (FMS), Sotera Health Co (SHC), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD), Park Dental Partners, Inc. (PARK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.